Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen, Jing; Zhang, Yong; Petrus, Michael N; Xiao, Wenming; Nicolae, Alina; Raffeld, Mark; Pittaluga, Stefania; Bamford, Richard N; Nakagawa, Masao; Ouyang, Sunny Tianyi; Epstein, Alan L; Kadin, Marshall E; Del Mistro, Annarose; Woessner, Richard; Jaffe, Elaine S; Waldmann, Thomas A.
Proc Natl Acad Sci U S A
; 114(15): 3975-3980, 2017 04 11.
Artigo em Inglês | MEDLINE | ID: mdl-28356514
Molecular modeling-driven approach for identification of Janus kinase 1 inhibitors through 3D-QSAR, docking and molecular dynamics simulations.
Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.
Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-Î³.
Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function.
Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.
Effects of hypnotic bromovalerylurea on microglial BV2 cells.
Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.